https://mindmedicinelaw.com/briefing/dea-procurement-quota-certification-extension-implications-for-psychedelic-resea-20260923-44272The Psychedelic Journalen2026-09-23T22:05:28.462423+00:00DEA Procurement Quota Certification Extension: Implications for Psychedelic Research Accessdea quota extension, psychedelic research compliance, controlled substances recordkeeping, federal register 2026, procurement quota certification, research access barriers, schedule i psychedelics, policy implications, clinical trial delayshttps://mindmedicinelaw.com/briefing/neurothera-expands-u-s-patents-for-lsd-and-ketamine-compounds-20260923-44584The Psychedelic Journalen2026-09-23T22:05:12.070399+00:00NeuroThera Expands U.S. Patents for LSD and Ketamine Compoundsneurothera, patents, lsd, ketamine, psychedelic therapeutics, market exclusivity, research freedom, uspto, clinical trials, intellectual propertyhttps://mindmedicinelaw.com/briefing/optimi-health-s-psilocybin-production-implications-for-clinical-trials-and-suppl-20260923-44583The Psychedelic Journalen2026-09-23T22:04:55.789090+00:00Optimi Health's Psilocybin Production: Implications for Clinical Trials and Supply in Canadaoptimi health, psilocybin production, canada, clinical trials, supply chain, health canada, special access program, gmp compliance, psychedelic researchhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-in-new-zealand-45-000-cost-raises-equity-questions-20260923-44582The Psychedelic Journalen2026-09-23T22:04:33.917149+00:00MDMA-Assisted Therapy in New Zealand: $45,000 Cost Raises Equity Questionsmdma-assisted therapy, ptsd treatment, psychedelic medicine, new zealand health policy, treatment cost, health equity, payer coverage, clinical trial protocols, regulatory approval, mental health accesshttps://mindmedicinelaw.com/briefing/dea-proposes-psychedelic-bans-amid-fda-push-for-legal-therapies-20260923-44580The Psychedelic Journalen2026-09-23T22:04:11.233105+00:00DEA Proposes Psychedelic Bans Amid FDA Push for Legal Therapiesdea scheduling, fda psychedelic guidance, psychedelic therapy access, clinical trial regulation, controlled substances act, research barriers, public health policy, investor risk, us drug policy, regulatory uncertaintyhttps://mindmedicinelaw.com/briefing/fda-debars-sanjay-kumar-for-5-years-drug-import-felony-signals-enforcement-shift-20260923-44286The Psychedelic Journalen2026-09-23T15:07:38.652801+00:00FDA Debars Sanjay Kumar for 5 Years: Drug Import Felony Signals Enforcement Shiftfda debarment, drug importation, psychedelic research compliance, supply chain risk, counterfeit drugs, clinical trial regulation, federal register, controlled substances, regulatory enforcementhttps://mindmedicinelaw.com/briefing/neurothera-and-clearmind-expand-us-patents-for-psychedelic-drug-combos-20260923-44415The Psychedelic Journalen2026-09-23T15:07:22.381036+00:00NeuroThera and Clearmind Expand US Patents for Psychedelic Drug Combospsychedelic patents, lsd ketamine ibogaine, combination therapy, uspto, intellectual property, clinical research, market access, drug development, neurothera, clearmindhttps://mindmedicinelaw.com/briefing/us-zero-tariff-policy-for-specialty-pharmaceuticals-implications-for-psychedelic-20260923-44266The Psychedelic Journalen2026-09-23T15:06:45.419226+00:00US Zero-Tariff Policy for Specialty Pharmaceuticals: Implications for Psychedelic Researchzero-tariff policy, specialty pharmaceuticals, orphan drugs, psychedelic research, import costs, federal register, public input process, trade policy, pharmaceutical ingredients, urgent health needhttps://mindmedicinelaw.com/briefing/ketamine-esketamine-and-scopolamine-in-trd-systematic-review-insights-2026-20260923-44343The Psychedelic Journalen2026-09-23T15:06:31.722551+00:00Ketamine, Esketamine, and Scopolamine in TRD: Systematic Review Insights (2026)treatment-resistant depression, ketamine, esketamine, scopolamine, rapid-acting antidepressants, systematic review, clinical trials, relapse prevention, FDA approval, psychiatryhttps://mindmedicinelaw.com/briefing/optimi-s-gmp-psilocybin-capsules-advance-australian-clinical-trials-20260923-44418The Psychedelic Journalen2026-09-23T15:06:15.115637+00:00Optimi's GMP Psilocybin Capsules Advance Australian Clinical Trialsoptimi health, psilocybin capsules, gmp compliance, australian clinical trials, therapeutic goods administration, psychedelic research, regulatory policy, investigational drugs, supply chain, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/ketamine-therapy-approved-for-veterans-with-ptsd-in-u-s-policy-shift-20260923-44417The Psychedelic Journalen2026-09-23T15:05:39.293168+00:00Ketamine Therapy Approved for Veterans With PTSD in U.S. Policy Shiftketamine therapy, veterans mental health, ptsd treatment, va approval, psychedelic policy, clinical trials, insurance coverage, public health, esketamine, trauma carehttps://mindmedicinelaw.com/briefing/dea-proposes-schedule-i-for-five-tryptamine-psychedelics-in-us-20260923-44255The Psychedelic Journalen2026-09-23T15:05:09.690029+00:00DEA Proposes Schedule I for Five Tryptamine Psychedelics in USdea scheduling, tryptamine psychedelics, schedule i substances, psychedelic research restrictions, controlled substances act, 4-oh-dipt, 5-meo-amt, clinical trial barriers, policy implications, harm reductionhttps://mindmedicinelaw.com/briefing/definium-s-phase-3-anxiety-trial-5-1-point-gap-signals-psychedelic-progress-20260923-44419The Psychedelic Journalen2026-09-23T15:04:47.990283+00:00Definium’s Phase 3 Anxiety Trial: 5.1-Point Gap Signals Psychedelic Progressdefinium therapeutics, phase 3 anxiety trial, psychedelic-based therapy, anxiolytic development, clinical significance, fda expedited review, trial design, safety profile, regulatory submission, market implicationshttps://mindmedicinelaw.com/briefing/optimi-health-s-clinical-leadership-shift-psilocybin-mdma-trials-in-focus-canada-20260922-44253The Psychedelic Journalen2026-09-22T22:04:59.446043+00:00Optimi Health’s Clinical Leadership Shift: Psilocybin & MDMA Trials in Focus (Canada, 2026)optimi health, psilocybin trials, mdma clinical development, canadian psychedelic regulation, health canada, clinical trial leadership, psychedelic-assisted therapy, drug development strategy, regulatory riskhttps://mindmedicinelaw.com/briefing/va-expands-psilocybin-research-policy-and-access-implications-for-u-s-veterans-20260922-44254The Psychedelic Journalen2026-09-22T22:04:18.197829+00:00VA Expands Psilocybin Research: Policy and Access Implications for U.S. Veteransva psilocybin research, veterans mental health, psychedelic clinical trials, federal policy psychedelics, treatment-resistant depression, ptsd veterans, access to psychedelic therapy, public health innovationhttps://mindmedicinelaw.com/briefing/dmt-harmine-formulation-alters-eeg-microstates-in-controlled-trial-20260922-44177The Psychedelic Journalen2026-09-22T22:04:05.797090+00:00DMT/Harmine Formulation Alters EEG Microstates in Controlled Trialdmt, harmine, eeg microstates, psychedelic brain dynamics, clinical trial design, neural signal diversity, metastability, biomarkers, ayahuasca-inspired formulationhttps://mindmedicinelaw.com/briefing/optimi-health-reshuffles-leadership-in-psychedelic-depression-and-ptsd-trials-20260922-44096The Psychedelic Journalen2026-09-22T15:07:12.815354+00:00Optimi Health Reshuffles Leadership in Psychedelic Depression and PTSD Trialsoptimi health, psychedelic clinical trials, depression research, ptsd treatment, leadership change, health canada, trial design, psilocybin, regulatory strategyhttps://mindmedicinelaw.com/briefing/fda-shifts-from-animal-to-nonclinical-testing-policy-impacts-20260922-43950The Psychedelic Journalen2026-09-22T15:06:20.438983+00:00FDA Shifts from 'Animal' to 'Nonclinical' Testing: Policy Impactsfda policy, nonclinical testing, psychedelic drug development, preclinical safety, animal alternatives, in vitro models, regulatory innovation, clinical trial design, drug approval processhttps://mindmedicinelaw.com/briefing/fda-s-shift-from-animal-to-nonclinical-testing-policy-impact-20260922-43951The Psychedelic Journalen2026-09-22T15:06:03.785237+00:00FDA’s Shift from ‘Animal’ to ‘Nonclinical’ Testing: Policy Impactfda policy, nonclinical testing, animal testing alternatives, psychedelic drug development, preclinical research, regulatory innovation, federal register, drug safety assessment, in vitro methods, neuropsychiatric drug trialshttps://mindmedicinelaw.com/briefing/fda-s-psychedelic-therapy-decisions-implications-for-us-policy-20260921-44581The Psychedelic Journalen2026-09-23T22:05:47.435704+00:00FDA’s Psychedelic Therapy Decisions: Implications for US Policyfda psychedelic therapy, psychedelic drug approval, mdma-assisted therapy, psilocybin clinical trials, risk evaluation and mitigation strategies, mental health policy, insurance coverage psychedelics, dea scheduling, post-marketing surveillancehttps://mindmedicinelaw.com/briefing/ketamine-gaba-and-glutamate-new-meta-analysis-in-depression-research-20260921-44189The Psychedelic Journalen2026-09-22T22:05:09.519349+00:00Ketamine, GABA, and Glutamate: New Meta-Analysis in Depression Researchketamine, depression, gaba, glutamate, magnetic resonance spectroscopy, biomarkers, clinical trial design, neurotransmitters, systematic review, psychedelic researchhttps://mindmedicinelaw.com/briefing/5-ht1b-receptor-a-new-focus-in-psychedelic-depression-research-20260921-44178The Psychedelic Journalen2026-09-22T22:04:31.085351+00:005-HT1B Receptor: A New Focus in Psychedelic Depression Researchserotonin 1b receptor, 5-ht1br, depression, anxiety, psychedelic drug development, psilocybin mechanism, clinical trial design, pet biomarkers, neuropharmacologyhttps://mindmedicinelaw.com/briefing/psilocybin-education-demand-among-chronic-pain-patients-in-canada-20260921-43977The Psychedelic Journalen2026-09-22T15:07:28.239621+00:00Psilocybin Education Demand Among Chronic Pain Patients in Canadapsilocybin education, chronic pain, canada, patient survey, public health, mental health comorbidity, cannabis comparison, health equity, psychedelic researchhttps://mindmedicinelaw.com/briefing/psilocybin-for-treatment-resistant-depression-evidence-and-regulatory-outlook-20260921-44011The Psychedelic Journalen2026-09-22T15:06:41.000349+00:00Psilocybin for Treatment-Resistant Depression: Evidence and Regulatory Outlookpsilocybin, treatment-resistant depression, clinical trials, psychedelic therapy, safety profile, regulatory policy, psychological support, mechanism of action, mental health innovationhttps://mindmedicinelaw.com/briefing/cell-death-pathways-and-depression-implications-for-psychedelic-therapeutics-20260920-44022The Psychedelic Journalen2026-09-22T15:07:57.284924+00:00Cell Death Pathways and Depression: Implications for Psychedelic Therapeuticscell death pathways, depression neurobiology, neuroinflammation, psychedelic clinical trials, neuroplasticity, biomarkers, antidepressant targets, regulated cell death, mitochondrial dysfunctionhttps://mindmedicinelaw.com/briefing/who-isop-2026-pharmacovigilance-curriculum-global-drug-safety-standards-and-psyc-20260920-43996The Psychedelic Journalen2026-09-22T15:07:42.557799+00:00WHO-ISoP 2026 Pharmacovigilance Curriculum: Global Drug Safety Standards and Psychedelic Medicinepharmacovigilance, who-isop curriculum, psychedelic medicine, drug safety monitoring, regulatory compliance, clinical trials, real-world evidence, risk communication, advanced therapies, public health policyhttps://mindmedicinelaw.com/briefing/ketamine-lidocaine-infusion-pilot-outcomes-in-refractory-neuropathic-pain-2026-s-20260920-44023The Psychedelic Journalen2026-09-22T15:06:58.336644+00:00Ketamine-Lidocaine Infusion: Pilot Outcomes in Refractory Neuropathic Pain (2026, Single-Center Study)ketamine-lidocaine infusion, refractory neuropathic pain, pain biomarkers, pilot clinical trial, intravenous ketamine, chronic pain management, adverse effects, policy implications, biomarker correlation, combination analgesic therapyhttps://mindmedicinelaw.com/briefing/psychedelics-and-suicidality-clinical-risks-and-guidance-global-review-2026-20260919-44299The Psychedelic Journalen2026-09-23T15:05:59.751783+00:00Psychedelics and Suicidality: Clinical Risks and Guidance (Global Review, 2026)psychedelics and suicidality, clinical trial safety, psilocybin risks, LSD suicide risk, integration protocols, screening for suicide risk, mechanisms of psychedelic action, policy recommendations, adverse event reporting, psychedelic therapy guidelineshttps://mindmedicinelaw.com/briefing/ferroptosis-pathways-in-major-depressive-disorder-implications-for-neuropsychiat-20260918-44027The Psychedelic Journalen2026-09-22T15:08:19.041249+00:00Ferroptosis Pathways in Major Depressive Disorder: Implications for Neuropsychiatric Researchferroptosis, major depressive disorder, neuroinflammation, oxidative stress, neuroplasticity, psychedelic research, biomarkers, preclinical models, iron metabolism, antioxidant signalinghttps://mindmedicinelaw.com/briefing/fda-weighs-psychedelic-therapies-as-behavioral-health-groups-push-for-system-rea-20260918-44014The Psychedelic Journalen2026-09-22T15:05:47.121875+00:00FDA Weighs Psychedelic Therapies as Behavioral Health Groups Push for System Readinessfda public hearing, psychedelic therapies, system readiness, behavioral health policy, workforce training, equitable access, clinical implementation, regulatory approval, infrastructure, mental health disparitieshttps://mindmedicinelaw.com/briefing/dmn-connectivity-after-es-ketamine-vs-antidepressants-in-mdd-20260917-44351The Psychedelic Journalen2026-09-23T15:07:01.691513+00:00DMN Connectivity After (Es)ketamine vs. Antidepressants in MDDdefault mode network, dmn connectivity, major depressive disorder, ketamine, antidepressants, functional connectivity, treatment-resistant depression, biomarkers, clinical trials, neuroimaginghttps://mindmedicinelaw.com/briefing/structure-based-design-of-subtype-selective-psychedelics-policy-and-research-imp-20260917-44251The Psychedelic Journalen2026-09-22T22:04:43.042203+00:00Structure-Based Design of Subtype-Selective Psychedelics: Policy and Research Impactpsychedelic analogs, structure-based drug design, serotonin receptor subtypes, 5-HT2A selectivity, clinical trial design, regulatory policy, intellectual property, drug scheduling, side effect reductionhttps://mindmedicinelaw.com/briefing/systematic-review-cognitive-effects-of-es-ketamine-in-mood-disorders-20260914-43871The Psychedelic Journalen2026-09-22T22:05:25.600342+00:00Systematic Review: Cognitive Effects of (Es)ketamine in Mood Disordersketamine, esketamine, cognitive effects, systematic review, depression, bipolar disorder, clinical safety, FDA, psychiatric treatment, risk-benefit assessment